Alphatec Holdings, Inc. (ATEC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call revealed strong financial performance, including a 25% increase in annual revenue and a 61% increase in Q4 adjusted EBITDA. The raised guidance for 2026 and positive free cash flow are optimistic indicators. Despite some risks in adoption rates and regulatory challenges, the overall sentiment is positive, supported by strategic growth investments and improved margins. Given the market cap of approximately $1.45 billion, these factors suggest a positive stock price reaction in the short term.
Key Financial Performance
Q4 2025 Revenue $213 million, a 20% increase year-over-year. This growth was driven by a 21% increase in surgical revenue and a 20% growth in same-store sales in established territories. The increase was attributed to continued surgeon adoption and procedural volume growth.
Full Year 2025 Revenue $764 million, a 25% increase year-over-year, representing $153 million in growth. This was driven by a 26% increase in surgical revenue and a 15% increase in EOS revenue, supported by procedural volume growth of 22% and average revenue per procedure growth of 3%.
Adjusted EBITDA (Q4 2025) $33 million, a 61% increase year-over-year, with nearly 400 basis points of improvement. This was driven by cost rationalization actions taken in 2024 and disciplined execution.
Adjusted EBITDA (Full Year 2025) $93 million, a 720 basis points improvement year-over-year, representing a $63 million increase. This was attributed to revenue growth and structural improvements in variable costs.
Free Cash Flow (Q4 2025) $8 million, at the favorable end of the $6 million to $8 million range. This was supported by $21 million in cash from operating activities and investments in surgical instruments.
Free Cash Flow (Full Year 2025) $3 million, marking the first full year of positive free cash flow. This was achieved through $45 million in cash from operating activities and $42 million reinvested into the business.
Non-GAAP Gross Margin (Q4 2025) 70.5%, an 80 basis points increase year-over-year, driven by product mix, volume leverage, and improving asset efficiency.
Non-GAAP Gross Margin (Full Year 2025) 70.2%, flat compared to the prior year, supported by volume leverage and asset efficiency.
Non-GAAP R&D Expense (Q4 2025) $14 million, up $0.5 million year-over-year, reflecting continued investment in long-term growth.
Non-GAAP R&D Expense (Full Year 2025) $57 million, approximately 7% of sales, a 140 basis points improvement year-over-year, reflecting strategic growth investments.
Non-GAAP SG&A Expense (Q4 2025) $118 million, approximately 55% of sales, a 12% increase year-over-year. This drove over 400 basis points of operating margin expansion due to leveraging foundational infrastructure investments and improved variable selling expenses.
Non-GAAP SG&A Expense (Full Year 2025) $449 million, approximately 59% of sales, a 790 basis points improvement year-over-year, reflecting scalability and structural improvements.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Bone mineral density test: Released out of EOS in 2025, along with pediatric tools and advancements in cervical retractor and segmental plating system (SPS).
3D-printed implants: Full line released in 2025, along with a corpectomy device and various biologics.
Valence platform: A fully integrated platform for navigation and robotic precision, set for controlled release in 2026.
Theradaptive partnership: Exclusive distribution partnership for a next-generation BMP product, expected to be a significant advancement in bone formation and safety.
Lateral surgery market: Expanded addressable market by training surgeons who previously used posterior approaches. Dominating the lateral space with increasing clinical relevance.
Deformity imaging market: EOS Edge Systems growth has provided access to previously inaccessible accounts. EOS Insight adoption has doubled implant usage growth rate within six months.
Revenue growth: Achieved $213 million in Q4 2025 revenue (20% YoY growth) and $764 million for the full year (25% YoY growth).
Adjusted EBITDA: $33 million in Q4 2025 (61% YoY growth) and $93 million for the full year (12% of revenue).
Free cash flow: Positive $8 million in Q4 2025 and $3 million for the full year, marking the first full year of positive free cash flow.
Gross margin: Non-GAAP gross margin of 70.5% in Q4 2025, up 80 basis points YoY.
Procedural ecosystem: Focused on creating clinical distinction through proceduralization, particularly in lateral and deformity surgeries.
International growth: Focal international growth strategy to expand market presence.
Sales force expansion: Continued investment in expanding and elevating the sales force to drive adoption and utilization.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Disruption: The market remains disrupted, which could pose challenges to maintaining consistent growth and stability.
International Revenue Mix: The international business carries a lower average revenue per case, creating a 120 basis point mix headwind that offsets U.S. growth.
Seasonality in Deformity Business: Seasonality in the deformity business has caused variations in quarterly revenue growth, potentially masking underlying momentum and complicating financial forecasting.
Cost Rationalization: The company is still lapping the impact of cost rationalization actions taken in 2024, which could affect profitability and operational efficiency.
Surgeon Adoption and Utilization: While surgeon adoption and utilization are growing, reliance on these metrics for revenue growth could be a risk if adoption rates slow or utilization patterns change.
Regulatory and Competitive Risks: The company’s reliance on proprietary technologies like SafeOp and EOS Insight creates a competitive moat, but also exposes it to risks if competitors develop similar or superior technologies or if regulatory challenges arise.
Supply Chain and Investment Risks: Continued investment in surgical instruments and inventory to support growth could strain cash flow if not managed effectively.
Economic and Market Conditions: Economic uncertainties and market conditions could impact the company’s ability to achieve its revenue and profitability targets.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects revenue growth of 17% in 2026, reaching approximately $890 million. This includes $805 million in surgical revenue and $85 million in EOS revenue.
Surgeon Adoption and Utilization: Continued strong surgeon adoption and utilization are expected to drive mid-teens volume growth and low single-digit revenue per surgery growth in 2026. Historical trends suggest significant case volume growth from existing surgeons.
Adjusted EBITDA: The company has increased its adjusted EBITDA guidance for 2026 to $134 million, representing a 15% adjusted EBITDA margin for the full year.
Gross Margin: Margins are expected to approach 71% as the company exits 2026, driven by asset efficiency and cost improvement efforts.
Free Cash Flow: The company expects to generate at least $20 million in free cash flow in 2026, supported by strong profitability and disciplined investment in instruments and inventory.
Product Development and Market Expansion: The company plans a controlled release of the Valence platform throughout 2026, targeting the replacement cycle for Stealth systems. Additionally, the company aims to expand lateral surgery applications and deepen its presence in deformity surgery.
Theradaptive Partnership: The company anticipates launching an advanced BMP product in several years, which is expected to outperform current market alternatives in bone formation and safety.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you confirm the details regarding the 4Q revenues, EBITDA, and 2026 revenue and EBITDA guidance?
A:Yes, the 4Q revenues were preannounced and came in line, EBITDA was about 10% higher than consensus, and the 2026 revenue guidance of $890 million was preannounced in January. The EBITDA guidance for 2026 has been increased.
Q:Can you provide details on the seasonal patterns and cadence for 2026, starting with the first quarter?
A:The full year growth is 17%. For seasonality, Q1 is expected to be about 22.1% of sales, Q2 about 24.5%, and Q3 about 25.5%, based on 2025 seasonality patterns. EBITDA is expected to have more drop-through in Q1 and slightly lower in the rest of the year, leading to an overall 32%.
Q:What are you seeing in terms of attracting sales personnel and any specific territorial strengths?
A:The hiring algorithm is performing as expected, and the company is a preferred destination for sales personnel. There is strong demand for the portfolio from both surgeons and salespeople, but no specific territorial dynamics were disclosed.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on territorial dynamics when asked about particular strengths or penetration in certain areas.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATEC Faithful
ATEC Full
ATEC distinction
ATEC market
Deformity
EOS Edge
EOS Insight
EOS volume
Ladies gentleman
addition
adoption EOS
asset efficiency
base
cash activity
chart left
contribution
efficiency Non
improvement basis
instrument
issue
leverage asset
leverage improvement
margin improvement
momentum
point margin
point mix
product development
relationship
relevance ecosystem
sale channel
sale improvement
scale
seasonality
self fund
surgeon utilization
surgeon year
teen
utilization surgeon
volume leverage
ATEC Transcript
Alphatec Holdings, Inc. (ATEC) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral5-12
Alphatec Holdings, Inc. (ATEC) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary indicates a revenue shortfall due to underperformance in EOS sales, which negatively impacts financial results and strategic goals. The lack of discussion on strategic initiatives and shareholder returns further weakens the sentiment. The absence of positive catalysts like new partnerships or optimistic guidance, coupled with unclear management responses in the Q&A, suggests a negative market reaction. Given the market cap, the stock is likely to experience a moderate negative movement.
Alphatec Holdings, Inc. (ATEC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Alphatec Holdings, Inc. (ATEC) Q4 2025 Earnings Call Transcript
Positive2-24
The company's earnings call revealed strong financial performance, including a 25% increase in annual revenue and a 61% increase in Q4 adjusted EBITDA. The raised guidance for 2026 and positive free cash flow are optimistic indicators. Despite some risks in adoption rates and regulatory challenges, the overall sentiment is positive, supported by strategic growth investments and improved margins. Given the market cap of approximately $1.45 billion, these factors suggest a positive stock price reaction in the short term.
ATEC Slides
ATEC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
